Navigation Links
MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine
Date:8/22/2012

RENO, Nev. A novel treatment in development at the University of Nevada School of Medicine for the most common form of muscular dystrophy is advancing towards human trials with a $308,000 boost from the Muscular Dystrophy Association.

The grant will be used to expand successful research by Associate Professor of Pharmacology Dean Burkin that has shown his laminin-111 protein therapy prevents the onset of the devastating neuromuscular disease in mouse models.

"The early results for laminin-111 as a therapeutic agent for (Duchenne muscular dystrophy) are really exciting," Sanjay Bidichandani, MDA vice president of research, said. "We are eager to see this research go forward."

Duchenne muscular dystrophy is a lethal genetic disease that affects one in 3,500 newborn boys and is caused by mutations in the gene encoding dystrophin. There is no effective treatment or cure.

At the time of diagnosis, DMD patients usually have developed significant muscle disease. The three-year grant will help determine if Burkin's therapy is effective at preventing or reversing disease progression after onset.

"What we aim to discover now is if this therapy is effective at preventing or reversing disease progression after it has already started," he said. "First we will determine if laminin-111 prevents muscle damage after disease onset, preserves muscle function and improves survival of mouse models of DMD. Second, we will determine if laminin-111 prevents cardiomyopathy in mouse models of DMD.

"Finally, in collaboration with researchers at Texas A&M, we will determine if a human version of the protein prevents muscle disease in other animals afflicted with the disease. Results from these studies will pave the way towards developing human recombinant laminin-111 protein as a novel therapeutic for DMD."

Demonstrating that the human version has efficacy in animals with DMD will move this therapy closer to a Food and Drug Administration investigational drug application and potential human clinical trials.

"This MDA grant is a tremendous help in moving this technology forward," Burkin said. "Patients have been waiting a long time for therapies to come about and I think we're at the cusp of major discoveries. Theoretically, laminin-111 protein therapy should be able to treat all patients with Duchenne muscular dystrophy."

Since laminin-111 is a naturally occurring protein already present in our kidneys and other tissues, Burkin said there is a better likelihood that it would not be rejected by the human body.

A postdoctoral researcher in Burkin's lab, Ryan Wuebbles, also received an $180,000 MDA development grant over three years to investigate if laminin fragments can be therapeutic for the treatment of DMD. Wuebbles plans to test different parts of laminin-111 in cells cultured from animals and people with the disease. The most promising of these will be tested and compared to those generated by the full-length protein.

Burkin's work has been funded by the National Institutes of Health and he has a patent license agreement with a biotech company to develop the laminin technology.

His research has been profiled in the internationally acclaimed Better World Report, the American Journal of Pathology and the Proceedings of the National Academy of Sciences. He co-hosted the Myomatrix 2012 conference in April, which brought together 73 international scientists and clinicians to the University of Nevada, Reno campus to explore and share their latest findings and data on treatment breakthroughs related to congenital muscular dystrophy. The results of the Myomatrix Conference were published in the July issue of Neuromuscular Disorders.

In an article published in June in Science Translational Medicine Burkin summarized the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy.


'/>"/>
Contact: Mike Wolterbeek
mwolterbeek@unr.edu
University of Nevada, Reno
Source:Eurekalert  

Related biology news :

1. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
2. NOAA science supports New Yorks offshore energy planning
3. Leading childhood asthma group supports federal asthma action plan to reduce disparities
4. New compound holds promise for treating Duchenne MD, other inherited diseases
5. New genetically engineered mice aid understanding of incurable neuromuscular disease
6. Real-life spider men using protein found in venom to develop muscular dystrophy treatment
7. Low oxygen levels may decrease life-saving protein in spinal muscular atrophy
8. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
9. Research reveals first evidence of hunting by prehistoric Ohioans
10. Diabetes Research Institute develops oxygen-generating biomaterial
11. APS issues new policy requiring identification of sex or gender in reporting scientific research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology: